| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF6B |
| Uniprot No | O95407 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-246aa |
| 氨基酸序列 | MRALEGPGLS LLCLVLALPA LLPVPAVRGV AETPTYPWRD AETGERLVCA QCPPGTFVQR PCRRDSPTTC GPCPPRHYTQ FWNYLERCRY CNVLCGEREE EARACHATHN RACRCRTGFF AHAGFCLEHA SCPPGAGVIA PGTPSQNTQC QPCPPGTFSA SSSSSEQCQP HRNCTALGLA LNVPGSSSHD TLCTSCTGFP LSTRVPGAEE CERAVIDFVA FQDISIKRLQ RLLQALEAPE GWGPTP |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF6B(DcR3)重组蛋白的模拟参考文献示例(注：内容为虚构，仅作格式参考)：
---
1. **"Structural and functional characterization of recombinant TNFRSF6B as a decoy receptor for TL1A"**
*Authors: Chen L, et al.*
**摘要**: 本研究通过大肠杆菌系统表达并纯化了重组TNFRSF6B蛋白，解析其晶体结构，证实其通过结合TL1A配体抑制NF-κB信号通路，为炎症性肠病的治疗提供潜在靶点。
2. **"Recombinant DcR3 modulates apoptosis in lung cancer cells by antagonizing FasL signaling"**
*Authors: Wang Y, et al.*
**摘要**: 利用哺乳动物细胞表达的重组DcR3蛋白可阻断FasL介导的肿瘤细胞凋亡，揭示其在肺癌微环境中通过免疫逃逸促进肿瘤进展的机制。
3. **"Development of a high-yield purification protocol for TNFRSF6B and its therapeutic evaluation in rheumatoid arthritis models"**
*Authors: Kim S, et al.*
**摘要**: 优化重组TNFRSF6B的HEK293细胞表达体系，验证其在小鼠类风湿性关节炎模型中通过中和TNF家族配体减轻关节炎症的效果。
4. **"DcR3 recombinant protein suppresses macrophage activation in sepsis via competitive binding to LIGHT"**
*Authors: Rodriguez M, et al.*
**摘要**: 通过体外实验证明，重组DcR3蛋白通过竞争性结合LIGHT蛋白，抑制巨噬细胞过度活化，改善脓毒症模型小鼠的生存率。
---
以上文献为模拟内容，实际研究中需通过学术数据库(如PubMed、Web of Science)检索真实文献。
TNFRSF6B, also known as Decoy Receptor 3 (DCR3), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). It functions as a soluble decoy receptor that binds to TNF-related ligands, including Fas ligand (FasL), LIGHT (TNFSF14), and TL1A (TNFSF15), thereby neutralizing their biological activities. Unlike most TNF receptors, TNFRSF6B lacks a transmembrane domain and is secreted extracellularly. This unique feature allows it to modulate immune responses by competitively inhibiting ligand-receptor interactions, which play critical roles in apoptosis, inflammation, and immune regulation.
The recombinant TNFRSF6B protein is typically produced using engineered expression systems, such as mammalian cells (e.g., HEK293 or CHO cells) or bacterial systems, to ensure proper post-translational modifications and functionality. Purification techniques like affinity chromatography are employed to obtain high-purity, bioactive forms of the protein. Researchers utilize this recombinant protein to study its immunomodulatory effects, particularly in contexts like autoimmune diseases, cancer, and inflammatory disorders. For example, elevated TNFRSF6B levels have been observed in certain tumors, suggesting its role in evading immune surveillance by blocking pro-apoptotic signals.
Additionally, recombinant TNFRSF6B serves as a valuable tool for structural studies, ligand-receptor interaction assays, and therapeutic development. Its potential as a biomarker or therapeutic target is under investigation, with studies exploring strategies to either enhance its anti-inflammatory effects or inhibit its activity in pathological conditions. Understanding TNFRSF6B's dual roles in immune homeostasis and disease progression remains a key focus in both basic and translational research.
×
